Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-05-23
DOI
10.1111/apt.15297
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver
- (2018) Hemant Shah et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set
- (2018) Christopher Ma et al. Clinical Gastroenterology and Hepatology
- Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review for Development of a Core Outcome Set
- (2018) Christopher Ma et al. Clinical Gastroenterology and Hepatology
- Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials
- (2018) Ferdinando D’Amico et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease
- (2018) Jenny H. Xie et al. GASTROENTEROLOGY
- 906 - Efficacy and Safety of Upadacitinib Maintenance Treatment for Moderate to Severe Crohn's Disease: Results from the Celest Study
- (2018) Julian Panes et al. GASTROENTEROLOGY
- Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
- (2018) Jean-Frédéric Colombel INFLAMMATORY BOWEL DISEASES
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2018) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life
- (2018) Paschalis Paschos et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- JAK inhibition in inflammatory bowel disease
- (2017) Pablo Olivera et al. Expert Review of Clinical Immunology
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
- (2017) L.C.S. De Vries et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
- (2017) Abhinav Vasudevan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
- (2016) Stefanos Bonovas et al. Clinical Gastroenterology and Hepatology
- Next generation of small molecules in inflammatory bowel disease
- (2016) Pablo Olivera et al. GUT
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
- (2016) Anthony L. Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes
- (2016) René Galien Pharmacological Reports
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
- (2015) Himal Lal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine kinase-2 gene polymorphisms are associated with ulcerative colitis and Crohn's disease in Turkish Population
- (2015) Güray Can et al. Clinics and Research in Hepatology and Gastroenterology
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease
- (2012) M. D. Long et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biology and significance of the JAK/STAT signalling pathways
- (2012) Hiu Kiu et al. GROWTH FACTORS
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Proteins Encoded in Genomic Regions Associated with Immune-Mediated Disease Physically Interact and Suggest Underlying Biology
- (2011) Elizabeth J. Rossin et al. PLoS Genetics
- Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn’s Disease in the Japanese Population
- (2009) Kayoko Sato et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
- (2008) P. D. R. HIGGINS et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
- (2008) Jeffrey C Barrett et al. NATURE GENETICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now